SCHEMBL5547302

SCHEMBL5547302

CC1(CN2CCN(Cc3ccc(F)cc3)C2=O)CO1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.54
TP53 P04637 1/20 0.49
POLB P06746 3/20 0.47
ALDH1A1 P00352 3/20 0.47
TSHR P16473 4/20 0.44
HDAC1 Q13547 1/20 0.43
GRM2 Q14416 1/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 2/20 0.41
SCD O00767 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.39
CYP11B2 P19099 1/20 0.39
ERCC1 P07992 1/20 0.39
ERCC4 Q92889 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540098 0.87 ERCC1 (0.52) POLBALDH1A1TSHRGRM2LMNA
SCHEMBL5539132 0.86 HSD11B1 (0.46) RAB9ATP53POLBALDH1A1TSHR
SCHEMBL5539716 0.86 KMT2A (0.54) POLBALDH1A1HDAC1LMNAKDM4E
SCHEMBL5545330 0.84 GAA (0.51) POLBALDH1A1HDAC1GRM2LMNA
SCHEMBL5546700 0.73 KCNH2 (0.57) RAB9ATP53POLBALDH1A1TSHR
SCHEMBL5544692 0.69 CHRM3 (0.53) CYP2D6CYP2C9CYP2C19
SCHEMBL5538972 0.69 KDM4E (0.41) ALDH1A1HDAC1KDM4E
SCHEMBL5539273 0.69 BTK (0.47) POLBALDH1A1TSHRHDAC1LMNA
SCHEMBL5542390 0.69 RAB9A (0.51) RAB9AHDAC1KMT2AMEN1
SCHEMBL17138490 0.68 PER2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAB9A 2824/4885TP53 4494/4885POLB 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.